1. Engineering modular integrated construction for high-rise building: a case study in Hong Kong. Issue 6 (15th April 2019) Authors: Shan, Sidi; Looi, Daniel; Cai, Yancheng; Ma, Peng; Chen, Man-Tai; Su, Ray; Young, Ben; Pan, Wei Journal: Proceedings of ICE Issue: Volume 172:Issue 6(2019) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 023 Relapse outcomes with natalizumab Q4W vs switch to Q6W. Issue 6 (27th May 2022) Authors: Butzkueven, Helmut; Kappos, Ludwig; Spelman, Tim; Trojano, Maria; Wiendl, Heinz; Su, Ray; Hyde, Robert; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 044 Safety and efficacy of dimethyl fumarate in ESTEEM UK cohort. Issue 6 (27th May 2022) Authors: Ford, Helen L; Su, Ray; Parks, Becky; Syndercombe, Fiona; Jones, Cynthia J Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 014 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program. Issue 6 (27th May 2022) Authors: Nicholas, Richard; Harrower, Timothy; Su, Ray; Licata, Stephanie; Vonsy, Jean Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate. (January 2021) Authors: Scott, Thomas F.; Su, Ray; Xiong, Kuangnan; Altincatal, Arman; Castrillo-Viguera, Carmen; Naylor, Maria L. Journal: Therapeutic advances in neurological disorders Issue: Volume 14(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). (September 2021) Authors: Butzkueven, Helmut; Kappos, Ludwig; Spelman, Tim; Trojano, Maria; Wiendl, Heinz; Su, Ray; Liao, Shirley; Hyde, Robert; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Therapeutic advances in neurological disorders Issue: Volume 14(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. (April 2021) Authors: Wiendl, Heinz; Spelman, Tim; Butzkueven, Helmut; Kappos, Ludwig; Trojano, Maria; Su, Ray; Campbell, Nolan; Ho, Pei-Ran; Licata, Stephanie Journal: Multiple sclerosis Issue: Volume 27:Number 5(2021) Page Start: 719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). (March 2021) Authors: Butzkueven, Helmut; Trojano, Maria; Kappos, Ludwig; Spelman, Tim; Wiendl, Heinz; Rosales, Karen; Su, Ray; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Multiple sclerosis Issue: Volume 27:Number 3(2021) Page Start: 410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗